Tempei Otsubo    Department   School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine    Position   Professor
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Effect of high-dose milnacipran in patients with depression.
Journal	Formal name：Neuropsychiatric disease and treatment Abbreviation：Neuropsychiatr Dis Treat ISSN code：11766328/11766328
Domestic / Foregin	Foregin
Volume, Issue, Page	3(5),pp.699-702
Author and coauthor	Hayashi Masatoshi, Mimura Masaru, Otsubo Tempei, Kamijima Kunitoshi
Publication date	2007
Summary	To investigate the antidepressant effect of high-dose milnacipran, we retrospectively compared three groups of inpatients with major depression; those who were given milnacipran >100-150 mg/day (high-dose milnacipran group), those treated with milnacipran at maximum doses of 50-100 mg/day (standard-dose milnacipran group), and those treated with paroxetine at maximum doses of 40 mg/day (paroxetine group). The Hamilton Depression Rating Scale (HAM-D) scores of the three groups showed significant decrease at discharge compared to the scores at admission, indicating improvement of depressive symptoms for each group. However, the mean HAM-D score on admission was significantly lower for the standard-dose milnacipran group than the high-dose milnacipran and paroxetine groups. Additional intermediate assessment of the high-dose milnacipran group showed that the effect of milnacipran was dose-dependent with an additional improvement when patients were increase from 100 to 150 mg/day. These results suggest that patients suffering from moderate to severe depression with relative high HAM-D scores may benefit from treatment with high-dose milnacipran.
PMID	19300602